Alzheimer’s disease (AD), the most common form of dementia, accounts for approximately two-thirds of all cases. At the pathological level, the disease is characterized by extracellular amyloidal beta (Aβ) protein deposits and intracellular neurofibrillary tangles (NT). The brain deposits of Aβ initiate a series of pathological reactions leading to microglia-mediated chronic inflammation. Neuroinflammation and oxidative stress processes are responsible for the impairment of the neurovascular working leading to axonal demyelination, local hypoxia-ischemia, white matter damages, and finally progressive loss of neurons and synapsis.

Despite the availability of huge data on its pathogenesis, a limited number of therapies for AD have emerged until now. Natural compounds could 214represent an important strategy for preventing or delaying the functional decline in AD’s patients due to their antioxidants and anti-inflammatory properties. It is worth noting that many in vitro and in vivo studies using natural compounds combined with antioxidants for AD treatment have been conducted so far. Among the wide range of nutraceuticals studied for this scope, the anti-inflammatory, antioxidant, antiamyloid, and anti-tau properties of Nigella sativa and its constituent thymoquinone, (−)-epigallocatechin-3-gallate, and curcumin may offer interesting neuroprotective benefits and translational perspectives into clinical practice.